To rule out that TCRV and LCMV could use alternative entry pathways, which may be also contributing to infection and thus be targeted by the activity of MYH9, we tested the specific inhibitors chlorpromazine (CME), nystatin (caveolae), 5-(N-ethyl-N-isopropyl)amiloride (EIPA) (macropinocytosis), and wortmannin (phagocytosis) prior to and during viral infection, as described above. This evidence concerns the gene MYH9 and viral infectious disease.